Authors: SEABER EJ PECK RW SMITH DA ALLANSON J HEFTING NR VANLIER JJ SOLLIE FAE WEMER J JONKMAN JHG

Citation: Ej. Seaber et al., THE ABSOLUTE BIOAVAILABILITY AND EFFECT OF FOOD ON THE PHARMACOKINETICS OF ZOLMITRIPTAN IN HEALTHY-VOLUNTEERS, British journal of clinical pharmacology, 46(5), 1998, pp. 433-439

Authors: PECK RW SEABER EJ DIXON RM LAYTON GR WEATHERLEY BC JACKSON SHD ROLAN PE POSNER J

Citation: Rw. Peck et al., THE PHARMACODYNAMICS AND PHARMACOKINETICS OF THE 5HT(1B 1D)-AGONIST ZOLMITRIPTAN IN HEALTHY-YOUNG AND ELDERLY MEN AND WOMEN/, Clinical pharmacology and therapeutics, 63(3), 1998, pp. 342-353

Authors: SEABER EJ GILLOTIN C MOHANLAL R LAYTON G POSNER J PECK R

Citation: Ej. Seaber et al., LACK OF INTERACTION BETWEEN PIZOTIFEN AND THE NOVEL ANTIMIGRAINE COMPOUND ZOLMITRIPTAN IN HEALTHY-VOLUNTEERS, Clinical drug investigation, 14(3), 1997, pp. 221-225

Authors: PECK RW SEABER EJ DIXON R GILLOTIN CG WEATHERLEY BC LAYTON G POSNER J

Citation: Rw. Peck et al., THE INTERACTION BETWEEN PROPRANOLOL AND THE NOVEL ANTIMIGRAINE AGENT ZOLMITRIPTAN (311C90), British journal of clinical pharmacology, 44(6), 1997, pp. 595-599

Authors: SEABER EJ RIDOUT G LAYTON G POSNER J PECK RW

Citation: Ej. Seaber et al., THE NOVEL ANTIMIGRAINE COMPOUND ZOLMITRIPTAN (ZOMIG 311C90) HAS NO CLINICALLY SIGNIFICANT INTERACTIONS WITH PARACETAMOL OR METOCLOPRAMIDE, European Journal of Clinical Pharmacology, 53(3-4), 1997, pp. 229-234